中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 35 Issue 5
May  2019
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2019  >  35(5): 1057-1060

Effect of silibinin on liver aminotransferases in patients with nonalcoholic fatty liver disease: A meta-analysis

DOI: 10.3969/j.issn.1001-5256.2019.05.024

  • Department of Hepatopancreatobiliary and Splenic Medicine, Affiliated Hospital of Logistics University of Chinese People's Armed Police Forces

Research funding:

 

  • Received Date: 2018-11-26
  • Published Date: 2019-05-20
    Abstract
  • Objective To conduct a meta-analysis of the articles on the effect of silibinin on aminotransferases in patients with nonalcoholic fatty liver disease ( NAFLD) , and to investigate the liver-protecting effect of silibinin in patients with NAFLD. Methods CNKI, Wanfang Data, VIP, SinoMed, PubMed, MEDLINE, Embase, and ScienceDirect were searched for randomized controlled trials ( RCTs) on the treatment of NAFLD patients with silibinin, The articles were screened according to inclusion and exclusion criteria, and then quality assessment and data extraction were performed. RevMan 5. 3 was used to perform the meta-analysis. Results A total of 8 articles with 665 patients were included. After 8 weeks to 3 months of silibinin treatment, there were significant reductions in the serum levels of alanine aminotransferase ( ALT) ( weighted mean difference [WMD]=-11. 60, 95% confidence interval [CI]:-18. 68 to-4. 51, P = 0. 001) and aspartate aminotransferase ( AST) ( WMD =-11. 56, 95% CI:-16. 93 to-6. 18, P < 0. 001) . Conclusion Silibinin can significantly reduce the serum levels of ALT and AST in patients with NAFLD.

     

    • FullText(HTML)
  • loading
    • References(21)
  • [1] GEORGE J, ANSTEE Q, RATZIU V, et al. NAFLD:The evolving landscape[J]. J Hepatol, 2018, 68 (2) :227-229.
    [2] ROSSO C, MEZZABOTTA L, GAGGINI M, et al. Peripheral insulin resistance predicts liver damage in nondiabetic subjects with nonalcoholic fatty liver disease[J]. Hepatology, 2016, 63 (1) :107-116.
    [3] CHALASANI N, YOUNOSSI Z, LAVINE JE, et al. The diagnosis and management of nonalcoholic fatty liver disease:Practice guidance from the American Association for the Study of Liver Diseases[J]. Hepatology, 2018, 67 (1) :328-357.
    [4] ZHAO ZH, LIU XL, FAN JG. Research on the natural history of non-alcoholic fatty liver disease should be taken seriously[J]. Chin J Hepatol, 2017, 25 (2) :81-84. (in Chinese) 赵泽华, 刘晓琳, 范建高.重视非酒精性脂肪性肝病自然史的研究[J].中华肝脏病杂志, 2017, 25 (2) :81-84.
    [5] CHAN WK, MUSTAPHA RNR, MAHADEVA S. A randomized trial of silymarin for the treatment of nonalcoholic steatohepatitis[J]. Clin Gastroenterol Hepatol, 2017, 15 (12) :1940-1949.
    [6] LU XL, DONG L, ZHANG KX, et al. Observation on the therapeutic efficacy of silibinin capsules for patients with fatty liver disease[J]. J Pract Hepatol, 2008, 11 (6) :398-400. (in Chinese) 鲁晓岚, 董蕾, 张宽学, 等.水飞蓟宾治疗脂肪肝的疗效观察[J].实用肝脏病杂志, 2008, 11 (6) :398-400.
    [7] MA ZQ. Clinical analysis of silibin-phosphatidylcholine treated the 61 cases alcoholicfattyliver[J]. Pract J Card Cereb Pneumal Vasc Dis, 2008, 4 (16) :29-30. (in Chinese) 马臻奇.水飞蓟宾-磷脂酰胆碱治疗酒精性脂肪肝61例临床分析[J].实用心脑肺血管病杂志, 2008, 4 (16) :29-30.
    [8] HAJIAGHAMOHAMMADI AA, ZIAEE A, OVEISI S, et al. Effects of metformin, pioglitazone, and silymarin treatment on non-alcoholic fatty liver disease:A randomized controlled pilot study[J].Hepat Mon, 2012, 12:e6099.
    [9] HASHEMI SJ, HAJIANI E, SARDABI EH. A placebo-controlled trial of silymarin in patients with nonalcoholic fatty liver[J]. Hepat Mon, 2009, 9:265-270.
    [10] HUANG HX. Observation of therapeutic effects of Silibinin Capsules to treat sixty cases of nonalcoholic fatty liver disease[J].China Med Herald, 2011, 8 (7) :62-63. (in Chinese) 黄红霞.水林佳 (水飞蓟宾-磷脂复合物) 治疗非酒精性脂肪性肝病60例临床疗效观察[J].中国医药导报, 2011, 8 (7) :62-63.
    [11] MOHESN M, AMIRMANSOOR R, MOHAMMAD P, et al. Effects of silymarin on reducing liver aminotransferases in patients with nonalcoholic fatty liver diseases[J]. Govaresh, 2013, 18 (3) :181-185.
    [12] SOLHI H, GHAHREMANI R, KAZEMIFAR AM, et al. Silymarin in treatment of non-alcoholic steatohepatitis:A randomized clinical trial[J]. Caspian J Intern Med, 2014, 5:9-12.
    [13] LI Y. The Clinical efficacy of silibinin and its influence to life quality of NAFLD patients[J]. Inf Tradit Chin Med, 2017, 34 (4) :88-91. (in Chinese) 李颖.水飞蓟宾治疗非酒精性脂肪性肝病的疗效分析及对患者生存质量影响的研究[J].中医药信息, 2017, 34 (4) :88-91.
    [14] LI J. Epidemiology characteristics of nonalcoholic fatty liver disease in Asia[J]. J Clin Hepatol, 2018, 34 (12) :2515-2519. (in Chinese) 李婕.亚洲地区非酒精性脂肪性肝病的流行病学特点[J].临床肝胆病杂志, 2018, 34 (12) :2515-2519.
    [15] GUO ZQ, WANG QY, QI XS, et al. Recommenda tions for the diagnosis and management of nonalcoholic fatty Liver disease:Practice guidance from the American Association for the Study of Liver Diseases (2017) [J]. J Clin Hepatol, 2017, 33 (12) :2275-2277. (in Chinese) 郭泽淇, 王倩怡, 祁兴顺, 等.《2017年美国肝病学会非酒精性脂肪性肝病诊疗指导》摘译[J].临床肝胆病杂志, 2017, 33 (12) :2275-2277.
    [16] VECCHIONE G, GRASSELLI E, VOCI A, et al. Silybin counteracts lipid excess and oxidative stress in cultured steatotic hepatic cells[J]. World J Gastroenterol, 2016, 22 (26) :6016-6026.
    [17] FENG ZM, CHENG SQ. Effects of silibinin combined with lamivudine treating the liver cirrhosis with active hepatitis B[J].Chin Gen Pract, 2007, 10 (8) :659-661. (in Chinese) 冯自明, 程书权.水飞蓟宾联合拉米夫定治疗慢性乙型肝炎活动性肝硬化疗效分析[J].中国全科医学, 2007, 10 (8) :659-661.
    [18] LYU CJ, LI H, YANG ZF. Role of lipid metabolism in nonalcoholic fatty hepatopathy[J]. J Log Univ CAPF:Med Sci, 2013, 22 (2) :158-160. (in Chinese) 吕成娇, 李海, 杨占福.脂质代谢在非酒精性脂肪性肝病发病机制中的作用研究现状[J].武警后勤学院学报:医学版, 2013, 22 (2) :158-160.
    [19] LI QQ, ZHOU Q, NIU JQ. New advances in pharmacological mechanism of silymarin and re-investigation of its clinical values[J]. J Clin Hepatol, 2015, 31 (2) :315-316. (in Chinese) 李青权, 周强, 牛俊奇, 等.水飞蓟素药理机制新进展及临床价值再探讨[J].临床肝胆病杂志, 2015, 31 (2) :315-316.
    [20] HE XJ, YANG ZY, DU XL, et al. Clinical effect of Atorvastatin Calcium combined with Silibinin in the treatment of non-alcoholic fatty liver disease[J]. China Med Herald, 2017, 14 (14) :123-125, 130. (in Chinese) 贺小军, 杨振宇, 杜锡林, 等.阿托伐他汀钙联合水飞蓟宾治疗非酒精性脂肪肝的临床效果[J].中国医药导报, 2017, 14 (14) :123-125, 130.
    [21] LIANG MX, CAI XH. Current status of pharmacokinetics and clinical study of silibinin-phospholipid complex[J]. Chin J New Drugs, 2010, 19 (19) :1778-1780. (in Chinese) 梁明欣, 蔡雪虹.水飞蓟宾-磷脂复合物的药动学及临床研究现状[J].中国新药杂志, 2010, 19 (19) :1778-1780.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索
    Get Citation
    PDF
    XML

    Article Metrics

    Article views (1764) PDF downloads(439) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return